FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004696319> ?p ?o ?g. }

• W2004696319 endingPage "13" @default.
• W2004696319 startingPage "12" @default.
• W2004696319 abstract "In 2004, research into infectious diseases of the nervous system was shaped not only by the diverse pathogens, outcomes, and mechanisms of neural dysfunction but also by progress made in therapy and prevention. The role of infections continues to change, epidemiological studies show the emergence of new or the re-emergence of old maladies, and other diseases continue unabated. There are therapeutic interventions for some diseases; for others there are limited possibilities to change the disease course or ameliorate clinical signs and symptoms. Over the past decade, more than at any other time, we have seen changes in disease patterns that might result from changes in environmental cues or in microbial evolution. Infectious diseases of the nervous system now include severe acute respiratory syndrome, West Nile virus, Ebola, and variant Creutzfeldt-Jakob disease (vCJD). New instances of virus transmission of ebola haemorrhagic fever from non-human primates to hunters are emerging in Zaire, the Republic of Congo, and Gabon and have caused more than 264 deaths.1Leroy EM Rouquet P Formenty P et al.Multiple Ebola virus transmission events and rapid decline of central African wildlife.Science. 2004; 303: 387-390Crossref PubMed Scopus (526) Google Scholar vCJD, a lethal disease that affects young people, has rapidly emerged as part of the family of transmissible spongiform encephalopathies. These rare fatal neurodegenerative diseases of human beings and animals include kuru, scrapie, and chronic wasting disease, and are characterised by the accumulation in the brain of an insoluble protease-resistant isoform of the host-encoded cellular prion protein. In the past 20 years these diseases have become a major agricultural and economic threat. In the late 1970s, production of protein supplement for livestock from animal carcasses was linked to transmission of bovine spongiform encephalopathy; after an outbreak of which in dairy cows, 153 human beings developed vCJD. Health concerns were raised because the disease crosses the “species barrier” between cattle and human beings and adapts to different mammalian species.2Casalone C Zanusso G Acutis P et al.Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.Proc Natl Acad Sci USA. 2004; 101: 3065-3070Crossref PubMed Scopus (393) Google Scholar Diagnostic criteria for vCJD are being formulated. MRI shows high signal in the posterior thalamus in most people with vCJD. As subclinical infection precedes overt disease, research focuses on the development of sensitive assays for detection of minute amounts of prion protein in suspected cases. Proteomic, immunological, pathological, and molecular approaches to diagnosis are being developed. Refinements in such research have led to the identification of a second transmissible spongiform encephalopathy in cattle, which is characterised by the presence of prion-protein-immunopositive amyloid plaques, similar to those in sporadic CJD.2Casalone C Zanusso G Acutis P et al.Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.Proc Natl Acad Sci USA. 2004; 101: 3065-3070Crossref PubMed Scopus (393) Google Scholar Bioterrorism is a potential cause of lethal neurological infections.3Harrison SC Alberts B Ehrenfeld E et al.Discovery of antivirals against smallpox.Proc Natl Acad Sci USA. 2004; 101: 11178-11192Crossref PubMed Scopus (80) Google Scholar Concern increased after the deliberate release of Bacillus anthracis in the weeks after the September 11, 2001, attacks in the USA. This act highlighted the need to research the pathogenesis of and immune responses to organisms that are possible terrorist weapons. However, the need for joint efforts among the pharmaceutical and biotechnology industries with parallel governmental responses towards antiviral discovery has yet to be realised.3Harrison SC Alberts B Ehrenfeld E et al.Discovery of antivirals against smallpox.Proc Natl Acad Sci USA. 2004; 101: 11178-11192Crossref PubMed Scopus (80) Google Scholar On a more positive note, action has been taken to eradicate several deadly infections of the nervous system, on three pivotal research fronts: therapeutics, preventative vaccines, and microbial detection. The most remarkable advances in the prevention of nervous system infections have been in vaccine delivery and global eradication. The campaign for the eradication of poliomyelitis involved the vaccination of more than 2 billion children and reduced the global incidence of polio from 350 000 cases in 1998 to less than 800 in 2002. Polio will likely be eliminated within the next 1–2 years.4Roberts L Polio: health workers scramble to contain African epidemic.Science. 2004; 305: 24-25Crossref PubMed Scopus (12) Google Scholar Introduction of vaccines for serotypes of pneumococcus and Neisseria meningitis (the meningococcus) have substantially reduced the cases of meningitis for 2004. For the former, the incidence of invasive pneumococcal disease in children under age 2 years in Europe was 14–90 cases per 100 000.5Reinert RR Pneumococcal conjugate vaccines: a European perspective.Int J Med Microbiol. 2004; 294: 277-294Crossref PubMed Scopus (62) Google Scholar The meningococcus is a leading cause of meningitis and fulminant septicaemia worldwide. During epidemics in sub-Saharan Africa, incidence of 1000 cases per 100 000 people occurred. In 1996, an epidemic in several west African countries caused nearly 25 000 deaths. Another major epidemic happened from 2000 to 2001. Meningococcal serogroups A, B, and C are associated with the most morbitiy and mortalities. Meningococcal polysaccharide vaccines are either bivalent (groups A and C) or tetravalent (groups A, C, Y, and W135). Conjugate vaccines against meningococcus serotype C have noticeably reduced disease incidence, and global elimination of bacterial meningitis may be achievable6Trotter CL Andrews NJ Kaczmarski EB et al.Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.Lancet. 2004; 364: 365-367Summary Full Text Full Text PDF PubMed Scopus (510) Google Scholar when vaccines against all serotypes are available. The large-scale synthesis, pharmaceutical development, and clinical assessment of a conjugate Haemophilus influenzae type b (Hib) vaccine is now a possibility.7Verez-Bencomo V Fernandez-Santana V Hardy E et al.A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.Science. 2004; 305: 522-525Crossref PubMed Scopus (431) Google Scholar Such research shows that access to synthetic complex carbohydrate-based vaccines is feasible and provides a platform for vaccine delivery in the developing world. Indeed, more than 600 000 infant deaths occur annually in developing countries as a result of Hib-induced meningitis or pneumonia. The use of Hib polysaccharides requires technology that restricts global access to much needed vaccines. In the face of a “revolution” in infectious disease occurrence, persistence in research to advance diagnostics and therapeutics have produced some of the most substantial accomplishments in global public health. We have no conflicts of interest." @default.
• W2004696319 created "2016-06-24" @default.
• W2004696319 creator A5048851127 @default.
• W2004696319 creator A5057472361 @default.
• W2004696319 date "2005-01-01" @default.
• W2004696319 modified "2023-10-02" @default.
• W2004696319 title "Infections of the nervous system" @default.
• W2004696319 cites W1490397184 @default.
• W2004696319 cites W1600250250 @default.
• W2004696319 cites W2049807968 @default.
• W2004696319 cites W2125686513 @default.
• W2004696319 cites W2143873194 @default.
• W2004696319 cites W2160879811 @default.
• W2004696319 cites W2167884034 @default.
• W2004696319 doi "https://doi.org/10.1016/s1474-4422(04)00951-2" @default.
• W2004696319 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7129461" @default.
• W2004696319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15620853" @default.
• W2004696319 hasPublicationYear "2005" @default.
• W2004696319 type Work @default.
• W2004696319 sameAs 2004696319 @default.
• W2004696319 citedByCount "23" @default.
• W2004696319 countsByYear W20046963192013 @default.
• W2004696319 countsByYear W20046963192014 @default.
• W2004696319 countsByYear W20046963192015 @default.
• W2004696319 countsByYear W20046963192016 @default.
• W2004696319 countsByYear W20046963192017 @default.
• W2004696319 countsByYear W20046963192019 @default.
• W2004696319 countsByYear W20046963192020 @default.
• W2004696319 countsByYear W20046963192023 @default.
• W2004696319 crossrefType "journal-article" @default.
• W2004696319 hasAuthorship W2004696319A5048851127 @default.
• W2004696319 hasAuthorship W2004696319A5057472361 @default.
• W2004696319 hasBestOaLocation W20046963191 @default.
• W2004696319 hasConcept C118552586 @default.
• W2004696319 hasConcept C2779473830 @default.
• W2004696319 hasConcept C545706735 @default.
• W2004696319 hasConcept C55493867 @default.
• W2004696319 hasConcept C71924100 @default.
• W2004696319 hasConcept C86803240 @default.
• W2004696319 hasConceptScore W2004696319C118552586 @default.
• W2004696319 hasConceptScore W2004696319C2779473830 @default.
• W2004696319 hasConceptScore W2004696319C545706735 @default.
• W2004696319 hasConceptScore W2004696319C55493867 @default.
• W2004696319 hasConceptScore W2004696319C71924100 @default.
• W2004696319 hasConceptScore W2004696319C86803240 @default.
• W2004696319 hasIssue "1" @default.
• W2004696319 hasLocation W20046963191 @default.
• W2004696319 hasLocation W20046963192 @default.
• W2004696319 hasLocation W20046963193 @default.
• W2004696319 hasLocation W20046963194 @default.
• W2004696319 hasOpenAccess W2004696319 @default.
• W2004696319 hasPrimaryLocation W20046963191 @default.
• W2004696319 hasRelatedWork W1506200166 @default.
• W2004696319 hasRelatedWork W1995515455 @default.
• W2004696319 hasRelatedWork W2048182022 @default.
• W2004696319 hasRelatedWork W2080531066 @default.
• W2004696319 hasRelatedWork W2604872355 @default.
• W2004696319 hasRelatedWork W2748952813 @default.
• W2004696319 hasRelatedWork W2899084033 @default.
• W2004696319 hasRelatedWork W3031052312 @default.
• W2004696319 hasRelatedWork W3032375762 @default.
• W2004696319 hasRelatedWork W3108674512 @default.
• W2004696319 hasVolume "4" @default.
• W2004696319 isParatext "false" @default.
• W2004696319 isRetracted "false" @default.
• W2004696319 magId "2004696319" @default.
• W2004696319 workType "article" @default.